Editorial

Is transmitted drug resistance in HIV on the rise?

BMJ 2001; 322 doi: 10.1136/bmj.322.7294.1074 (Published 5 May 2001)
Cite this as: BMJ 2001;322:1074

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan J Little (slittle@ucsd.edu), assistant professor of medicine
  1. University of California Department of Medicine, UCSD Treatment Center, 150 W Washington Street, San Diego, CA 92103-2005, USA

    It seems so

    Papers p 1087

    The transmission of drug resistant variants of HIV-1 has the potential seriously to limit the therapeutic options of newly infected patients. The selection of HIV drug resistant variants among individuals who are already receiving treatment also clearly limits both the size and duration of the viral supression induced by drug treatment. 1 2 Reports from North America and Europe indicate that up to 14% of recently infected patients have been infected with a strain of virus bearing well characterised drug resistance mutations (in 1-10% of cases) or reduced susceptibility to a particular drug (2-14% of cases).3–5 Temporal trends in the transmission of drug resistance for these populations are not yet available, but a …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular